You are here

Press Release Archive

 
- Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial

(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the

 
- Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research

(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT® (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12—16 September 2008. Researchers will present results of several analyses evaluating the cost

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, President, Worldwide Pharmaceutical Operations, at the UBS Global Life Sciences Conference on Monday, September 22 at 2:00 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “UBS Global Life Sciences Conference

 
- Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation’s investigational drug for treatment of Alzheimer’s disease and Huntington’s disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer’s

 
- Lipitor 80 mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients with Heart Disease During the Five-Year TNT Trial

(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets

 
- Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011

(BUSINESS WIRE)--Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in challenges to two of its patents covering atorvastatin, the active ingredient in Lipitor. The basic (DK 171,588) and enantiomer (EP 409,281) patents were challenged by generics manufacturer Ranbaxy. The court ruled that the basic patent, which expires in November 2011, would be infringed

 
- Pfizer Says Vacation with Your Dog before the Summer Ends

(BUSINESS WIRE)--With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with their veterinarians about managing travel with their dog before the summer ends. Since Pfizer’s Cerenia™ (maropitant citrate) became the first-and-only veterinary approved canine medication in America, Europe and Canada to prevent vomiting from

 
- IAFF Launches Smoking Cessation Campaign with Pfizer

(BUSINESS WIRE)--The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking cigarettes. “Our goal is to help make the IAFF the first smoke-free union,” IAFF General President Harold Schaitberger said in his address to delegates at the IAFF 49th Convention. The IAFF is collaborating with pharmaceutical

 
- Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease

(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in

 
- Pfizer Reports Second-Quarter 2008 Results

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):                   ($ in millions, except per share amounts)    

 
- Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting

BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) in Chicago, July 26-31. Pfizer will also host an analyst briefing at ICAD

 
- Pfizer Fully Supports Updated PhRMA Code

(BUSINESS WIRE)--Pfizer endorses the updates to the PhRMA Code on Interactions with Healthcare Professionals and will fully comply with all aspects of the Code. The updated PhRMA Code demonstrates Pfizer’s commitment to working with our customers in an open and responsible manner. Along with other member companies of PhRMA, we’ve updated the code to address the concerns of many of our stakeholders

 
- Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows

(BUSINESS WIRE)--Pfizer announced today that new statin users who took Lipitor® (atorvastatin calcium) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims databases. The results were published in the July issue of Current Medical Research and Opinion. “It is

 
- Pfizer Changes Its Funding of Continuing Medical Education in the U.S.

(BUSINESS WIRE)--Pfizer today announced changes in the way it supports continuing medical education (CME) initiatives for U.S. healthcare professionals. Pfizer will continue to support CME programs at many of the world’s leading academic medical centers and teaching hospitals, as well as programs sponsored by associations, medical societies and community hospitals, in keeping with the shared goal of improving public health

 
- FDA Approves First and Only Single-Dose Antibiotic for Dogs and Cats

(BUSINESS WIRE)--Pfizer Animal Health has announced the Food and Drug Administration (FDA) has approved Convenia® (cefovecin sodium), the first and only antibiotic for dogs and cats available in a single veterinarian-administered injectable dose. Convenia provides up to 14 days of antibiotic treatment in a single dose for the most common skin infections in dogs and cats – the No. 1 reason pets are prescribed antibiotics.

 
- Pfizer Declares a 32-Cent Third Quarter 2008 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent third–quarter, 2008, dividend on the company’s common stock, payable September 3, 2008, to shareholders of record at the close of business on August 8, 2008. The third-quarter 2008 cash dividend will be the 279th consecutive quarterly dividend paid by Pfizer 

 
- Pfizer Invites Public to View and Listen to Webcast of July 23 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 11 a.m. Eastern Daylight Saving Time on Wednesday, July 23. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2008 Performance Report, to be issued that morning. To view and listen to the webcast and view the

 
- Pfizer Invites Public to View and Listen to Webcast of July 28 Pfizer Analyst and Investor Meeting at ICAD

(BUSINESS WIRE)--Pfizer Inc invites investors, media, and the general public to view and listen to a webcast of a presentation by Pfizer’s neuroscience leadership team at an analyst and investor meeting on Monday, July 28, at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the International Conference on Alzheimer’s Disease (ICAD). To view and listen to the webcast, visit our web site

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.